
Researchers investigated the effectiveness of upadacitinib, an oral selective Janus kinase (JAK) inhibitor, for treating moderate-to-severe Crohn's disease. Patients were randomly assigned to receive either 45 mg of upadacitinib or a placebo once daily for 12 weeks. Those who showed a clinical response to upadacitinib were then randomized in the U-ENDURE maintenance trial to receive 15 mg of upadacitinib, 30 mg of upadacitinib, or a placebo once daily for 52 weeks. The results demonstrated that upadacitinib was more effective than placebo in inducing and maintaining remission in Crohn's disease patients. However, some adverse events were observed, such as herpes zoster infections, hepatic disorders, neutropenia, and gastrointestinal perforations. Overall, upadacitinib showed promise as a potential treatment for Crohn's disease.
Like
Save
Share